Barrington analyst Michael Petusky raised his price target for LeMaitre Vascular to $37 from $32 following the company's "solid" Q2 results. The analyst is "encouraged" by recent sales trends and thinks the company's margins could expand "meaningfully" over the next couple of years. The recent geographic expansion and new product innovations, like the just-launched XenoSure Plus, will give LeMaitre a "reasonable opportunity" to sustain its recent pickup in organic momentum over the longer term, Petusky tells investors in a research note. He maintains an Outperform rating on the shares.